The current market price of Nippon India NIFTY Pharma ETF Growth Plan is ₹23.14. ETF prices fluctuate during market hours based on demand, supply, and movements in the underlying index or assets.

The Nippon India NIFTY Pharma ETF Growth Plan, managed by Nippon Life India Asset Management Limited, is an equity ETF focused on passive investment in the Nifty Pharma TRI index. This ETF replicates the Nifty Pharma TRI by investing in securities proportionally, ensuring that it mirrors the index's performance closely, with a minimal tracking error of 0.02%. The portfolio is heavily concentrated in the Pharmaceuticals & Biotechnology sector, with top holdings such as Sun Pharmaceutical Industries Limited at 22.2% and Divi's Laboratories Limited at 10.7%, indicating sector-specific risk. Over the past year, the ETF has delivered a change of 1.0%, reflecting its performance amidst market dynamics, although long-term performance metrics like CAGR for 3, 5, and 10 years are unavailable. With an AUM of ₹1022.9 Cr and a low expense ratio of 0.21%, this ETF is positioned as a cost-efficient option for investors seeking exposure to the pharmaceutical sector.

Nippon India NIFTY Pharma ETF Growth Plan is designed to track Nifty Pharma TRI, allowing investors to gain exposure to its underlying securities through a single investment.

The expense ratio of Nippon India NIFTY Pharma ETF Growth Plan is 0.21%. This represents the annual fee charged by the fund house for managing the ETF and is deducted from the fund’s assets.

The Assets Under Management (AUM) of Nippon India NIFTY Pharma ETF Growth Plan is approximately ₹1,007.47. AUM reflects the total market value of assets managed by the ETF and is often used as an indicator of fund size and liquidity.

Nippon India NIFTY Pharma ETF Growth Plan is classified under the Very High risk category. The risk level depends on the volatility of the underlying index, market conditions, and asset composition of the ETF.

The tracking error of Nippon India NIFTY Pharma ETF Growth Plan is 0.02%. Tracking error measures how closely the ETF’s performance matches its benchmark index over time.

Nippon India NIFTY Pharma ETF Growth Plan has a dividend yield of 0.70%. Dividend treatment depends on the ETF structure and fund house policy.

Based on available data, Nippon India NIFTY Pharma ETF Growth Plan has delivered the following returns: 1-year return: 3.54%. 3-year return: 3.54%. 5-year return: 3.54%. Past performance does not guarantee future results.

Before investing in Nippon India NIFTY Pharma ETF Growth Plan, investors generally consider the underlying index, expense ratio, tracking error, risk profile, liquidity, and how the ETF fits within their overall portfolio strategy.